On April 3, 2025, INmune Bio Inc. presented a poster at an international conference detailing patient demographics and biomarker status from their MINDFul Phase II trial for early Alzheimer's disease.
AI Assistant
INMUNE BIO INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.